Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX005N in Moderate-to-Severe Atopic Dermatitis (Ib/II)
CTR20211996Phase 2Completed
- Sponsor
- Qyuns Therapeutics
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing QX005N with Placebo (2 arms). Primary endpoints: Safety and tolerability: TEAEs, Safety and tolerability: injection site reactions and 4 more. Started Aug 2021; status: completed.
02
Drugs
QX005N
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20211996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211996.